Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) Global Opportunity Analysis and Industry Forecast up to 2026

July 2020 | 85 pages | ID: B630AB1E4A7AEN
IHR Insights

Abstracts

Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) Global Opportunity Analysis and Industry Forecast up to 2026

Biosimilars or follow-on-biologics are the 'duplicated' and authorized variants of those reference biologics that have experienced patent expiration. Biosimilars improvement and approval with reference biologics is a significant part of the general advancement and development process. Guidelines for biosimilars assume an essential job in keeping up the suitability and harmony among unique and biosimilars items. Different regulatory specialists, for example, EMA and FDA effectively control Biosimilars commercialization and advancement.

Research Methodology:

The biosimilars market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:

The market is driven by factors such as the rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs. However, market growth is limited by manufacturing complexities and resistance from biological manufacturers. Furthermore, the growth of the biosimilars market is hampered with multiple factors including the lack of regulatory guidelines, consumers’ brand preferences, the reluctance of physicians to prescribed biosimilars, and the high capital required for research and development.

Based on the parameter of manufacturing, the market of Biosimilars is segmented into two segments:

• In-house manufacturing
• Contract manufacturing

The in-house manufacturing segment makes up for the larger market share, while the contract manufacturing segment is expected to witness the highest CAGR during the forecasting period.

Based on the product, the biosimilars market monoclonal antibody industry is prominently segmented into trastuzumab, infliximab, rituximab, adalimumab, and other monoclonal antibodies. The infliximab segment accounted for the largest biosimilars market share in 2019. The growing prevalence of autoimmune diseases drives market growth.

Based on the indication, the market is segregated on the basis of:

• Oncology
• Blood Disorder
• Offsite Treatment
• Infectious Diseases
• Chronic Diseases
• Autoimmune Disease
• Other Diseases

The oncology segment accounts for a major share of the biosimilars market. The large share of this segment can be attributed to the high incidence of cancer across the globe.

Some of the major players in the domain of Biosimilars are Probiomed, Boehringer Ingelheim, Apotex, Fresenius Kabi, Gedeon Richter, Mabxience, Amega Biotech, Biocad, Coherus Biosciences, Stada Arzneimittel Ag, Dr. Reddy’s Laboratories, Mylan, Samsung Biologics, Amgen, Biocon, Celltrion, Teva Pharmaceutical, Eli Lilly, Pfizer, and Sandoz.

By Geography, the market of Biosimilars is further classified into North America, Europe, the Asia Pacific, and the rest of the World. North America accounted for the largest share. There are two important factors which are the driving forces behind the growth of Biosimilars market giving it CAGR of 23.9% during the forecast period. These two factors are:

Lower pricing than competing biologics

Rising incidence of chronic diseases

There are a lot of opportunities in emerging countries and this report will help in understanding the current market dynamics, changing needs, and innovations that might be needed to make the user experience enriching.

This report would be the foundation for any research on the Biosimilars, vendor capabilities, SWOT of the sensors, and organized framework for data analysis for further advanced innovation.

This piece of the report would be the backbone for exhaustive research and a tool for the upcoming innovations and technologies. This gives an idea about the major competitors in the market, their journey, and the competitive edge which one should have to beat other players in the market.

The report is having a qualitative analysis of the Biosimilars market and the opportunity which can be leveraged by the market in the current scenario

The market report would be delving into deep insights regarding the technological innovations

Contents

Executive Summary
Industry Outlook
Industry Overview
Industry Trends
Market Snapshot
Market Definition
Market Outlook
PEST Analysis
Porter Five Forces
Related Markets
Market characteristics
Market Evolution
Market Trends and Impact
Advantages/Disadvantages of Market
Regulatory Impact
Market Offerings
Market Segmentation
Market Dynamics
Drivers
Restraints
Opportunities
DRO - Impact Analysis
Indication: Market Size & Analysis
Overview
Autoimmune Disease
Blood Disorders
Infectious Disease
Chronic Disorder
Oncology
Offsite Treatment
Other Diseases
Type of Manufacturing: Market Size & Analysis
Overview
In-House Manufacturing
Contract Manufacturing
Product: Market Size & Analysis
Overview
Insulin
Recombinant human growth hormone (rhGH)
Granulocyte colony-stimulating factor
Interferon
Erythropoietin
Etanercept
Monoclonal antibodies
Rituximab
Infliximab
Adalimumab
Trastuzumab
Follitropin
Glucagon
Calcitonin
Teriparatide
Enoxaparin Sodium
Geography: Market Size & Analysis
Overview
North America
Europe
Asia Pacific
Rest of the World
Competitive Landscape
Competitor Comparison Analysis
Market Developments
Mergers and Acquisitions, Legal, Awards, Partnerships
Product Launches and execution
Vendor Profiles
Dr. Reddy’s Laboratories
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Stada Arzneimittel Ag
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Coherus Biosciences
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Biocad
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Amega Biotech
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Probiomed
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Boehringer Ingelheim
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Apotex
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Fresenius Kabi
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Gedeon Richter
Overview
Product Offerings
Geographic Revenue
Business Units
Developments
SWOT Analysis
Business Strategy
Companies to Watch
Mabxience
Overview
Market
Business Strategy
Sandoz
Overview
Market
Business Strategy
Pfizer
Overview
Market
Business Strategy
Eli Lilly
Overview
Market
Business Strategy
Teva Pharmaceutical
Overview
Market
Business Strategy
Celltrion
Overview
Market
Business Strategy
Biocon
Overview
Market
Business Strategy
Amgen
Overview
Market
Business Strategy
Samsung Biologics
Overview
Market
Business Strategy
Mylan
Overview
Market
Business Strategy
Analyst Opinion
Annexure
Report Scope
Market Definitions
Research Methodology
Data Collation and In-house Estimation
Market Triangulation
Forecasting
Report Assumptions
Declarations
Stakeholders
Abbreviations

Tables

TABLES

GLOBAL BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR AUTOIMMUNE DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INFECTIOUS DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CHRONIC DISORDER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR OFFSITE TREATMENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CONTRACT MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INSULIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR RHGH, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR GRANULOCYTE COLONY STIMULATING FACTOR, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INTERFERON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ERYTHROPOIETIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ETANERCEPT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR FOLLITROPIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR GLUCAGON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CALCITONIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR TERIPARATIDE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ENOXAPARIN SODIUM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
DR. REDDY’S LABORATORIES: OVERVIEW
DR. REDDY’S LABORATORIES: STRATEGIC SNAPSHOT
DR. REDDY’S LABORATORIES: BUSINESS FOCUS
DR. REDDY’S LABORATORIES: PRODUCT/SERVICE PORTFOLIO
STADA ARZNEIMITTEL AG: OVERVIEW
STADA ARZNEIMITTEL AG: STRATEGIC SNAPSHOT
STADA ARZNEIMITTEL AG: BUSINESS FOCUS
STADA ARZNEIMITTEL AG: PRODUCT/SERVICE PORTFOLIO
COHERUS BIOSCIENCES: OVERVIEW
COHERUS BIOSCIENCES: STRATEGIC SNAPSHOT
COHERUS BIOSCIENCES: BUSINESS FOCUS
COHERUS BIOSCIENCES: PRODUCT/SERVICE PORTFOLIO
BIOCAD: OVERVIEW
BIOCAD: STRATEGIC SNAPSHOT
BIOCAD: BUSINESS FOCUS
BIOCAD: PRODUCT/SERVICE PORTFOLIO
AMEGA BIOTECH: OVERVIEW
AMEGA BIOTECH: STRATEGIC SNAPSHOT
AMEGA BIOTECH: BUSINESS FOCUS
AMEGA BIOTECH: PRODUCT/SERVICE PORTFOLIO
PROBIOMED: OVERVIEW
PROBIOMED: STRATEGIC SNAPSHOT
PROBIOMED: BUSINESS FOCUS
PROBIOMED: PRODUCT/SERVICE PORTFOLIO
BOEHRINGER INGELHEIM: OVERVIEW
BOEHRINGER INGELHEIM: STRATEGIC SNAPSHOT
BOEHRINGER INGELHEIM: BUSINESS FOCUS
BOEHRINGER INGELHEIM: PRODUCT/SERVICE PORTFOLIO
APOTEX: OVERVIEW
APOTEX: STRATEGIC SNAPSHOT
APOTEX: BUSINESS FOCUS
APOTEX: PRODUCT/SERVICE PORTFOLIO
FRESENIUS KABI: OVERVIEW
FRESENIUS KABI: STRATEGIC SNAPSHOT
FRESENIUS KABI: BUSINESS FOCUS
FRESENIUS KABI: PRODUCT/SERVICE PORTFOLIO
GEDEON RICHTER: OVERVIEW
GEDEON RICHTER: STRATEGIC SNAPSHOT
GEDEON RICHTER: BUSINESS FOCUS
GEDEON RICHTER: PRODUCT/SERVICE PORTFOLIO

CHARTS

GLOBAL BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR AUTOIMMUNE DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INFECTIOUS DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CHRONIC DISORDER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR OFFSITE TREATMENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CONTRACT MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INSULIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR RHGH, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR GRANULOCYTE COLONY STIMULATING FACTOR, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR INTERFERON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ERYTHROPOIETIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ETANERCEPT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR FOLLITROPIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR GLUCAGON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR CALCITONIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR TERIPARATIDE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
GLOBAL BIOSIMILARS MARKET VALUE FOR ENOXAPARIN SODIUM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
REST OF WORLD BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)